NYSE:TMOLife Sciences
Thermo Fisher Scientific (TMO) Wins Kapiglucagon Contract, Is The Stock Still Undervalued?
Thermo Fisher Scientific (TMO) is back in focus after ImmuPharma selected the company to develop and manufacture the finished drug product for its experimental diabetes treatment Kapiglucagon, following a competitive tender process.
See our latest analysis for Thermo Fisher Scientific.
The Kapiglucagon contract lands as Thermo Fisher Scientific’s recent share price has climbed, with a 30-day share price return of 13.46% and a 90-day gain of 12.80%. The year-to-date share price return is still...